Company news

Cingulate Inc. news in 2022

Cingulate Inc.'s news releases, calls and decks from 2022, newest first.

View company

Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

November 13, 2022

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

October 31, 2022

Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

October 23, 2022

Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103

September 18, 2022

Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

August 10, 2022

Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

June 22, 2022

Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

May 23, 2022

Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

May 11, 2022

Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

March 9, 2022

Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

February 7, 2022

Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors

January 24, 2022

Decks in 2022